...A. We and our partners, Sanofi, as we look at the market opportunity, there's about 300,000 Type 2 COPD patients in the U.S. I think if you look at the G7 in totality, that number is about 550,000 patients. B. So yes, we received the CRL in October of 2023. C. We would then resubmit our sBLA for this indication, and hopefully, could be on track for an FDA decision in the first half of '25. D. I believe in the U.S., there's around 300,000 patients. E. We're obviously very excited about the prospects of the top line growth with continued growth from our DUPIXENT alliance with Sanofi as well as, obviously, the ophthalmology franchise. F. If you look at the expense side, just to give a little bit of qualitative color on cost of goods sold, we gave non-GAAP gross margin guidance of between 89% and 91% of net product sales. G. But as that facility ramps up in 2024 and gets fully implemented, we would expect those costs to be capitalized and sold through as product costs in the future. H. In terms...
